By Craig Adeyanju
On July 30, Pfizer (NYSE: PFE) announced that it had entered into a definitive agreement to acquire Baxter International’s (NYSE: BAX) portfolio of marketed vaccines in a deal that is reportedly worth $635 million.
The portfolio of vaccines consists of NeisVac-C and FSME-IMMUN/TicoVac.
The terms of the deal have include that Pfizer will also acquire a portion of Baxter’s Orth, Austria facility, where these vaccines are produced. Pfizer expects the deal to be completed by the end of the year.
In the meantime, though, here’s what this deal could mean for Pfizer